drugset
drugset / Trial / NCT05960617

Efficacy and Safety of Empagliflozin in GSD-Ib Patients

NCT05960617 ↗

Phase 2 Withdrawn Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

Empagliflozin Treatment of GSD-1b patients

Timeline

Start
2023-07-15
Primary completion
2024-06-30
Completion
2024-12-31

Outcome

Outcome not reported

Stopped (Enrollment): “The study was not initiated because the planned prospective design was no longer feasible in routine clinical practice before participant enrollment.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 0.3 mg/kg Oral

Indications

glycogen storage disease Ib